Zafirlukast inhibits complexation of lsr2 with DNA and growth of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2134-2140

  Pinault, Lucile ^a   Han, Jeong Sun ^b   Kang, Choong Min ^c   Franco, Jimmy ^d   Ronning, Donald R ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b Myong Ji University   (South Korea)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d MERRIMACK COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LSR2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG INTERACTION; ESCHERICHIA COLI; FLUORESCENCE POLARIZATION; GENE EXPRESSION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-ASTHMATIC AGENTS; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DNA-BINDING PROTEINS; DRUG REPOSITIONING; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; SPECIES SPECIFICITY; TOSYL COMPOUNDS; TRANSCRIPTION, GENETIC;

EID: 84876257708     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02407-12     Document Type: Article

References (34)

1. WHO. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland.
2. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, Dunbar D, Jost KC, Jr, Wallace C, Weis SE. 2011. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 11:19. doi:10.1186/1471-2458-11-19.
3. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2012. Totally drugresistant tuberculosis in India. Clin. Infect. Dis. 54:579-581.
4. Chang KC, Yew WW. 2013. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 18:8-21.
5. Chen JM, Ren H, Shaw JE, Wang YJ, Li M, Leung AS, Tran V, Berbenetz NM, Kocincova D, Yip CM, Reyrat JM, Liu J. 2008. Lsr2 of Mycobacterium tuberculosis is a DNA-bridging protein. Nucleic Acids Res. 36:2123-2135.
6. Gordon BR, Imperial R, Wang L, Navarre WW, Liu J. 2008. Lsr2 of Mycobacterium represents a novel class of H-NS-like proteins. J. Bacteriol. 190:7052-7059.
7. Colangeli R, Haq A, Arcus VL, Summers E, Magliozzo RS, McBride A, Mitra AK, Radjainia M, Khajo A, Jacobs WR, Jr, Salgame P, Alland D. 2009. The multifunctional histone-like protein Lsr2 protects mycobacteria against reactive oxygen intermediates. Proc. Natl. Acad. Sci. U. S. A. 106:4414-4418.
8. Ali SS, Xia B, Liu J, Navarre WW. 2012. Silencing of foreign DNA in bacteria. Curr. Opin. Microbiol. 15:175-181.
9. Gordon BR, Li Y, Wang L, Sintsova A, van Bakel H, Tian S, Navarre WW, Xia B, Liu J. 2010. Lsr2 is a nucleoid-associated protein that targets AT-rich sequences and virulence genes in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 107:5154-5159.
10. Chen JM, German GJ, Alexander DC, Ren H, Tan T, Liu J. 2006. Roles of Lsr2 in colony morphology and biofilm formation of Mycobacterium smegmatis. J. Bacteriol. 188:633-641.
11. Colangeli R, Helb D, Vilcheze C, Hazbon MH, Lee CG, Safi H, Sayers B, Sardone I, Jones MB, Fleischmann RD, Peterson SN, Jacobs WR, Jr, Alland D. 2007. Transcriptional regulation of multi-drug tolerance and antibiotic-induced responses by the histone-like protein Lsr2 in M. tuberculosis. PLoS Pathog. 3:e87. doi:10.1371/journal.ppat.0030087.
12. Lamichhane G, Tyagi S, Bishai WR. 2005. Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect. Immun. 73:2533-2540.
13. Sassetti CM, Boyd DH, Rubin EJ. 2001. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 98:12712-12717.
14. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48:77-84.
15. Villanueva J, Yanes O, Querol E, Serrano L, Aviles FX. 2003. Identification of protein ligands in complex biological samples using intensityfading MALDI-TOF mass spectrometry. Anal. Chem. 75:3385-3395.
16. Yanes O, Villanueva J, Querol E, Aviles FX. 2007. Detection of noncovalent protein interactions by 'intensity fading' MALDI-TOF mass spectrometry: applications to proteases and protease inhibitors. Nat. Protoc. 2:119-130.
17. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-1422.
18. De Smet KA, Weston A, Brown IN, Young DB, Robertson BD. 2000. Three pathways for trehalose biosynthesis in mycobacteria. Microbiology 146:199-208.
19. Jackett PS, Aber VR, Lowrie DB. 1978. Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J. Gen. Microbiol. 104:37-45.
20. Manganelli R, Dubnau E, Tyagi S, Kramer FR, Smith I. 1999. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol. Microbiol. 31:715-724.
21. Kulka K, Hatfull G, Ojha AK. 2012. Growth of Mycobacterium tuberculosis biofilms. J. Vis. Exp. 60:e3820. doi:10.3791/3820.
22. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43:717-731.
23. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE, III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279:40174-40184.
24. Stewart GR, Wernisch L, Stabler R, Mangan JA, Hinds J, Laing KG, Young DB, Butcher PD. 2002. Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays. Microbiology 148:3129-3138.
25. Wong DK, Lee BY, Horwitz MA, Gibson BW. 1999. Identification of Fur, aconitase, and other proteins expressed by Mycobacterium tuberculosis under conditions of low and high concentrations of iron by combined two-dimensional gel electrophoresis and mass spectrometry. Infect. Immun. 67:327-336.
26. Chauhan A, Lofton H, Maloney E, Moore J, Fol M, Madiraju MV, Rajagopalan M. 2006. Interference of Mycobacterium tuberculosis cell division by Rv2719c, a cell wall hydrolase. Mol. Microbiol. 62:132-147.
27. Vadrevu IS, Lofton H, Sarva K, Blasczyk E, Plocinska R, Chinnaswamy J, Madiraju M, Rajagopalan M. 2011. ChiZ levels modulate cell division process in mycobacteria. Tuberculosis (Edinb.) 91(Suppl 1):S128-S135.
28. Kalscheuer R, Syson K, Veeraraghavan U, Weinrick B, Biermann KE, Liu Z, Sacchettini JC, Besra G, Bornemann S, Jacobs WR, Jr. 2010. Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an alpha-glucan pathway. Nat. Chem. Biol. 6:376-384.
29. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810.
30. Miesel L, Weisbrod TR, Marcinkeviciene JA, Bittman R, Jacobs WR, Jr. 1998. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180:2459-2467.
31. Jarlier V, Nikaido H. 1990. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172:1418-1423.
32. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. 2000. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 39:185-201.
33. Dekhuijzen PN, Koopmans PP. 2002. Pharmacokinetic profile of zafirlukast. Clin. Pharmacokinet. 41:105-114.
34. Su SC, Hartkopf AV, Karger BL. 1976. High-performance ion-pair partition chromatography of sulfa drugs. Study and optimization of chemical parameters. J. Chromatogr. 119:523-537.